Provention prices diabetes drug above analysts’ estimates at $13,850/vial
By Raghav Mahobe and Nandhini Srinivasan (Reuters) -Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a …
provention
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022– -Company to host teplizumab …